Astellas Pharma Reports 23.4% Year-over-Year Revenue Growth in First Half Results
Astellas Pharma Inc. (ALPMY) has released its first-half financial results, reporting a significant revenue increase of 23.4% year-over-year to ¥1,270.86 billion. The company also reported GAAP earnings per share (EPS) of ¥134.47 for the period. Alongside these financial figures, the company provided updates regarding its fiscal year 2027 outlook. These results come amid a broader regulatory landscape involving new drug-pricing discussions between the U.S. administration and various biotechnology firms.